These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8946904)

  • 21. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 22. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 23. Looking for a miracle.
    Marchant J
    New Sci; 2000 Jun; 166(2244):16-7. PubMed ID: 11902203
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 25. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overdue process.
    Nat Biotechnol; 2004 Nov; 22(11):1329. PubMed ID: 15529137
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
    Daemmrich A; Krucken G
    Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
    [No Abstract]   [Full Text] [Related]  

  • 28. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
    Finkelstein PE
    AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
    [No Abstract]   [Full Text] [Related]  

  • 29. Market watch: Upcoming market catalysts in Q1 2018.
    Collins T
    Nat Rev Drug Discov; 2018 Dec; 17(1):8-9. PubMed ID: 29282372
    [No Abstract]   [Full Text] [Related]  

  • 30. Competitors try collaboration to speed drug development.
    Patlak M
    J Natl Cancer Inst; 2010 Jun; 102(12):841-3. PubMed ID: 20530762
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Food and Drug Administration responds to pressure for expanded drug access.
    Brower V
    J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
    [No Abstract]   [Full Text] [Related]  

  • 33. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 35. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 36. Drugs with breakthrough status charm investors.
    Senior M
    Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748
    [No Abstract]   [Full Text] [Related]  

  • 37. Practical, legal, and ethical issues in expanded access to investigational drugs.
    Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA revamps committee conflict-of-interest rules.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Oct; 98(19):1354-5. PubMed ID: 17018777
    [No Abstract]   [Full Text] [Related]  

  • 40. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.